CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Sell
25
EDIT Quote, Financials, Valuation and Earnings
Last price:
$1.31
Seasonality move
:
3.83%
Day range:
$1.31 - $1.40
52-week range:
$0.91 - $6.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.39x
P/B ratio:
0.82x
Volume:
2M
Avg. volume:
1.9M
1-year change:
-76.58%
Market cap:
$110.4M
Revenue:
$32.3M
EPS (TTM):
-$2.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
$706.1K | -$0.59 | -23.05% | -22.53% | $3.67 |
|
ADMA
ADMA Biologics
|
$118.7M | $0.13 | 42.17% | 75% | $25.74 |
|
EYPT
EyePoint Pharmaceuticals
|
$8.8M | -$0.69 | -36.13% | -25.42% | $33.00 |
|
OCGN
Ocugen
|
-- | -$0.06 | -100% | -- | $6.75 |
|
PTCT
PTC Therapeutics
|
$372.6M | -$0.71 | -8.88% | -1.55% | $60.87 |
|
TGTX
TG Therapeutics
|
$117.9M | $0.17 | 101.13% | 653.48% | $43.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
$1.33 | $3.67 | $110.4M | -- | $0.00 | 0% | 3.39x |
|
ADMA
ADMA Biologics
|
$23.61 | $25.74 | $5.6B | 28.79x | $0.00 | 0% | 13.45x |
|
EYPT
EyePoint Pharmaceuticals
|
$6.09 | $33.00 | $418.6M | -- | $0.00 | 0% | 7.92x |
|
OCGN
Ocugen
|
$0.66 | $6.75 | $193.3M | -- | $0.00 | 0% | 44.24x |
|
PTCT
PTC Therapeutics
|
$40.76 | $60.87 | $3.2B | 6.26x | $0.00 | 0% | 1.82x |
|
TGTX
TG Therapeutics
|
$34.86 | $43.50 | $5.5B | 145.25x | $0.00 | 0% | 14.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EDIT
Editas Medicine
|
-- | 0.641 | -- | 3.71x |
|
ADMA
ADMA Biologics
|
17.17% | 2.642 | 1.78% | 2.76x |
|
EYPT
EyePoint Pharmaceuticals
|
-- | -2.418 | -- | 7.57x |
|
OCGN
Ocugen
|
49.18% | 0.941 | 12.22% | 2.71x |
|
PTCT
PTC Therapeutics
|
285.85% | 0.499 | 7.08% | 3.76x |
|
TGTX
TG Therapeutics
|
-- | 1.159 | -- | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
-- | -$34.4M | -100% | -100% | -112.28% | -$51.3M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
EYPT
EyePoint Pharmaceuticals
|
$10.8M | -$45.2M | -50.34% | -50.34% | -356.36% | -$36.2M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
PTCT
PTC Therapeutics
|
$1.2B | $969.5M | -382.54% | -- | 81.96% | $867.6M |
|
TGTX
TG Therapeutics
|
$105.3M | $8.6M | 11.64% | 19.78% | 10.12% | -$25.7M |
Editas Medicine vs. Competitors
-
Which has Higher Returns EDIT or ADMA?
ADMA Biologics has a net margin of -148.33% compared to Editas Medicine's net margin of 95.19%. Editas Medicine's return on equity of -100% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About EDIT or ADMA?
Editas Medicine has a consensus price target of $3.67, signalling upside risk potential of 175.69%. On the other hand ADMA Biologics has an analysts' consensus of $25.74 which suggests that it could grow by 9.02%. Given that Editas Medicine has higher upside potential than ADMA Biologics, analysts believe Editas Medicine is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 ADMAADMA Biologics3 1 0 -
Is EDIT or ADMA More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.571, suggesting its less volatile than the S&P 500 by 42.882%.
-
Which is a Better Dividend Stock EDIT or ADMA?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or ADMA?
Editas Medicine quarterly revenues are $30.6M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Editas Medicine's net income of -$45.4M is lower than ADMA Biologics's net income of $111.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 28.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.39x versus 13.45x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.39x -- $30.6M -$45.4M ADMAADMA Biologics13.45x 28.79x $117.5M $111.9M
-
Which has Higher Returns EDIT or EYPT?
EyePoint Pharmaceuticals has a net margin of -148.33% compared to Editas Medicine's net margin of -357.26%. Editas Medicine's return on equity of -100% beat EyePoint Pharmaceuticals's return on equity of -50.34%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M EYPTEyePoint Pharmaceuticals92.96% -$0.64 $336.5M -
What do Analysts Say About EDIT or EYPT?
Editas Medicine has a consensus price target of $3.67, signalling upside risk potential of 175.69%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 441.87%. Given that EyePoint Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe EyePoint Pharmaceuticals is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 EYPTEyePoint Pharmaceuticals9 0 0 -
Is EDIT or EYPT More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.087%.
-
Which is a Better Dividend Stock EDIT or EYPT?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or EYPT?
Editas Medicine quarterly revenues are $30.6M, which are larger than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Editas Medicine's net income of -$45.4M is lower than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Editas Medicine's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.39x versus 7.92x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.39x -- $30.6M -$45.4M EYPTEyePoint Pharmaceuticals7.92x -- $11.6M -$41.4M
-
Which has Higher Returns EDIT or OCGN?
Ocugen has a net margin of -148.33% compared to Editas Medicine's net margin of -1816.75%. Editas Medicine's return on equity of -100% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About EDIT or OCGN?
Editas Medicine has a consensus price target of $3.67, signalling upside risk potential of 175.69%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 919.48%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 OCGNOcugen2 0 0 -
Is EDIT or OCGN More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.
-
Which is a Better Dividend Stock EDIT or OCGN?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or OCGN?
Editas Medicine quarterly revenues are $30.6M, which are larger than Ocugen quarterly revenues of $764K. Editas Medicine's net income of -$45.4M is lower than Ocugen's net income of -$13.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.39x versus 44.24x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.39x -- $30.6M -$45.4M OCGNOcugen44.24x -- $764K -$13.9M
-
Which has Higher Returns EDIT or PTCT?
PTC Therapeutics has a net margin of -148.33% compared to Editas Medicine's net margin of 73.68%. Editas Medicine's return on equity of -100% beat PTC Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M PTCTPTC Therapeutics98.91% $10.04 $100M -
What do Analysts Say About EDIT or PTCT?
Editas Medicine has a consensus price target of $3.67, signalling upside risk potential of 175.69%. On the other hand PTC Therapeutics has an analysts' consensus of $60.87 which suggests that it could grow by 49.33%. Given that Editas Medicine has higher upside potential than PTC Therapeutics, analysts believe Editas Medicine is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 PTCTPTC Therapeutics6 6 0 -
Is EDIT or PTCT More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.522, suggesting its less volatile than the S&P 500 by 47.837%.
-
Which is a Better Dividend Stock EDIT or PTCT?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or PTCT?
Editas Medicine quarterly revenues are $30.6M, which are smaller than PTC Therapeutics quarterly revenues of $1.2B. Editas Medicine's net income of -$45.4M is lower than PTC Therapeutics's net income of $866.6M. Notably, Editas Medicine's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is 6.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.39x versus 1.82x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.39x -- $30.6M -$45.4M PTCTPTC Therapeutics1.82x 6.26x $1.2B $866.6M
-
Which has Higher Returns EDIT or TGTX?
TG Therapeutics has a net margin of -148.33% compared to Editas Medicine's net margin of 4.19%. Editas Medicine's return on equity of -100% beat TG Therapeutics's return on equity of 19.78%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M TGTXTG Therapeutics87.14% $0.03 $237.3M -
What do Analysts Say About EDIT or TGTX?
Editas Medicine has a consensus price target of $3.67, signalling upside risk potential of 175.69%. On the other hand TG Therapeutics has an analysts' consensus of $43.50 which suggests that it could grow by 24.79%. Given that Editas Medicine has higher upside potential than TG Therapeutics, analysts believe Editas Medicine is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 TGTXTG Therapeutics5 0 0 -
Is EDIT or TGTX More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.
-
Which is a Better Dividend Stock EDIT or TGTX?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or TGTX?
Editas Medicine quarterly revenues are $30.6M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Editas Medicine's net income of -$45.4M is lower than TG Therapeutics's net income of $5.1M. Notably, Editas Medicine's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 145.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.39x versus 14.51x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.39x -- $30.6M -$45.4M TGTXTG Therapeutics14.51x 145.25x $120.9M $5.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
52
SRPT alert for May 8
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 23.38% over the past day.
